These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 21949656)

  • 21. Induction of autophagy through CLEC4E in combination with TLR4: an innovative strategy to restrict the survival of
    Pahari S; Negi S; Aqdas M; Arnett E; Schlesinger LS; Agrewala JN
    Autophagy; 2020 Jun; 16(6):1021-1043. PubMed ID: 31462144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. WNT6/ACC2-induced storage of triacylglycerols in macrophages is exploited by Mycobacterium tuberculosis.
    Brandenburg J; Marwitz S; Tazoll SC; Waldow F; Kalsdorf B; Vierbuchen T; Scholzen T; Gross A; Goldenbaum S; Hölscher A; Hein M; Linnemann L; Reimann M; Kispert A; Leitges M; Rupp J; Lange C; Niemann S; Behrends J; Goldmann T; Heine H; Schaible UE; Hölscher C; Schwudke D; Reiling N
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34255743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice.
    Dhar N; McKinney JD
    Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12275-80. PubMed ID: 20566858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. G1-4A, a Polysaccharide from Tinospora cordifolia Inhibits the Survival of Mycobacterium tuberculosis by Modulating Host Immune Responses in TLR4 Dependent Manner.
    Gupta PK; Chakraborty P; Kumar S; Singh PK; Rajan MG; Sainis KB; Kulkarni S
    PLoS One; 2016; 11(5):e0154725. PubMed ID: 27148868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multifaceted remodeling by vitamin C boosts sensitivity of Mycobacterium tuberculosis subpopulations to combination treatment by anti-tubercular drugs.
    Sikri K; Duggal P; Kumar C; Batra SD; Vashist A; Bhaskar A; Tripathi K; Sethi T; Singh A; Tyagi JS
    Redox Biol; 2018 May; 15():452-466. PubMed ID: 29413958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetics of Mycobacterium tuberculosis-specific IFN-γ responses and sputum bacillary clearance in HIV-infected adults during treatment of pulmonary tuberculosis.
    Mzinza DT; Sloan DJ; Jambo KC; Shani D; Kamdolozi M; Wilkinson KA; Wilkinson RJ; Davies GR; Heyderman RS; Mwandumba HC
    Tuberculosis (Edinb); 2015 Jul; 95(4):463-9. PubMed ID: 26051653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection.
    Sada-Ovalle I; Sköld M; Tian T; Besra GS; Behar SM
    Am J Respir Crit Care Med; 2010 Sep; 182(6):841-7. PubMed ID: 20508216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential requirement of formyl peptide receptor 1 in macrophages and neutrophils in the host defense against Mycobacterium tuberculosis Infection.
    Nafiz TN; Sankar P; Mishra LK; Rousseau RP; Saqib M; Subbian S; Parihar SP; Mishra BB
    Sci Rep; 2024 Oct; 14(1):23595. PubMed ID: 39384825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis.
    Verma RK; Agrawal AK; Singh AK; Mohan M; Gupta A; Gupta P; Gupta UD; Misra A
    Tuberculosis (Edinb); 2013 Jul; 93(4):412-7. PubMed ID: 23562366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Replication rates of Mycobacterium tuberculosis in human macrophages do not correlate with mycobacterial antibiotic susceptibility.
    Raffetseder J; Pienaar E; Blomgran R; Eklund D; Patcha Brodin V; Andersson H; Welin A; Lerm M
    PLoS One; 2014; 9(11):e112426. PubMed ID: 25386849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne's model of dormancy.
    Raghunandanan S; Jose L; Kumar RA
    J Antibiot (Tokyo); 2018 Nov; 71(11):939-949. PubMed ID: 30185901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isoniazid derivatives and their anti-tubercular activity.
    Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
    Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isoniazid (INH) treatment of INH-resistant Mycobacterium tuberculosis inhibits infected macrophage to produce TNF-alpha.
    Wibawa T; Pangemanan L; Rachmawaty FJ; Rintiswati N; Mustofa ; Soesatyo MH
    Southeast Asian J Trop Med Public Health; 2014 Sep; 45(5):1107-13. PubMed ID: 25417512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection.
    Manca C; Koo MS; Peixoto B; Fallows D; Kaplan G; Subbian S
    PLoS One; 2013; 8(8):e74082. PubMed ID: 24015316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isoniazid-resistant tuberculosis in Iran: A systematic review.
    Javad Nasiri M; Chirani AS; Amin M; Halabian R; Imani Fooladi AA
    Tuberculosis (Edinb); 2016 May; 98():104-9. PubMed ID: 27156625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis.
    Xu Y; Wang L; Zimmerman MD; Chen KY; Huang L; Fu DJ; Kaya F; Rakhilin N; Nazarova EV; Bu P; Dartois V; Russell DG; Shen X
    PLoS Pathog; 2018 Apr; 14(4):e1006974. PubMed ID: 29698476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
    Gegia M; Cohen T; Kalandadze I; Vashakidze L; Furin J
    Int J Tuberc Lung Dis; 2012 Jun; 16(6):812-6. PubMed ID: 22507372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjunctive Host-Directed Therapy With Statins Improves Tuberculosis-Related Outcomes in Mice.
    Dutta NK; Bruiners N; Zimmerman MD; Tan S; Dartois V; Gennaro ML; Karakousis PC
    J Infect Dis; 2020 Mar; 221(7):1079-1087. PubMed ID: 31605489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
    Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
    Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.